NEW YORK (GenomeWeb News) – Opko Health today announced it has granted UK-based International Health Technology the rights to offer a novel panel of protein biomarkers and an associated algorithm in parts of Europe for the detection of prostate cancer.

Under the terms of the deal, IHT will offer the biomarker panel in laboratory settings in the UK, Ireland, Sweden, and Denmark. Financial and other terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.